Cargando…

Probiotics in Inflammatory Bowel Disease: Are We Back to Square One?

Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the alimentary tract whose incidence has been increasing over the past few years. Even though there is a complex interplay of several factors in the pathogenesis of IBD, a decrease in the diversity of intestinal microbiome is co...

Descripción completa

Detalles Bibliográficos
Autores principales: Puvvada, Suvarna Rekha, Luvsannyam, Enkhmaa, Patel, Dhara, Hassan, Zaira, Hamid, Pousette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536108/
https://www.ncbi.nlm.nih.gov/pubmed/33042686
http://dx.doi.org/10.7759/cureus.10247
_version_ 1783590493234397184
author Puvvada, Suvarna Rekha
Luvsannyam, Enkhmaa
Patel, Dhara
Hassan, Zaira
Hamid, Pousette
author_facet Puvvada, Suvarna Rekha
Luvsannyam, Enkhmaa
Patel, Dhara
Hassan, Zaira
Hamid, Pousette
author_sort Puvvada, Suvarna Rekha
collection PubMed
description Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the alimentary tract whose incidence has been increasing over the past few years. Even though there is a complex interplay of several factors in the pathogenesis of IBD, a decrease in the diversity of intestinal microbiome is commonly found in patients. Extensive research is directed towards the alteration of this microbiome to improve the symptoms of IBD. Probiotics, prebiotics, antibiotics, and diet are studied in this regard extensively. Among them, probiotics have gained more interest as some of the studies showed them to be effective in decreasing gut inflammation in vitro and in vivo. Although there is no cure for IBD as of today, the available medications do decrease gut inflammation and help prolong remission and decrease relapse rates. But their side effects preclude their long-term use. Probiotics may be a ray of hope among IBD patients as they are apparently safe. This article reviews each of the available literature from the past 10 years to see if there is any certain role of probiotics in induction, maintenance of remission, prevention of relapse, and improvement in the quality of life in IBD patients.
format Online
Article
Text
id pubmed-7536108
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-75361082020-10-08 Probiotics in Inflammatory Bowel Disease: Are We Back to Square One? Puvvada, Suvarna Rekha Luvsannyam, Enkhmaa Patel, Dhara Hassan, Zaira Hamid, Pousette Cureus Internal Medicine Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the alimentary tract whose incidence has been increasing over the past few years. Even though there is a complex interplay of several factors in the pathogenesis of IBD, a decrease in the diversity of intestinal microbiome is commonly found in patients. Extensive research is directed towards the alteration of this microbiome to improve the symptoms of IBD. Probiotics, prebiotics, antibiotics, and diet are studied in this regard extensively. Among them, probiotics have gained more interest as some of the studies showed them to be effective in decreasing gut inflammation in vitro and in vivo. Although there is no cure for IBD as of today, the available medications do decrease gut inflammation and help prolong remission and decrease relapse rates. But their side effects preclude their long-term use. Probiotics may be a ray of hope among IBD patients as they are apparently safe. This article reviews each of the available literature from the past 10 years to see if there is any certain role of probiotics in induction, maintenance of remission, prevention of relapse, and improvement in the quality of life in IBD patients. Cureus 2020-09-04 /pmc/articles/PMC7536108/ /pubmed/33042686 http://dx.doi.org/10.7759/cureus.10247 Text en Copyright © 2020, Puvvada et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Puvvada, Suvarna Rekha
Luvsannyam, Enkhmaa
Patel, Dhara
Hassan, Zaira
Hamid, Pousette
Probiotics in Inflammatory Bowel Disease: Are We Back to Square One?
title Probiotics in Inflammatory Bowel Disease: Are We Back to Square One?
title_full Probiotics in Inflammatory Bowel Disease: Are We Back to Square One?
title_fullStr Probiotics in Inflammatory Bowel Disease: Are We Back to Square One?
title_full_unstemmed Probiotics in Inflammatory Bowel Disease: Are We Back to Square One?
title_short Probiotics in Inflammatory Bowel Disease: Are We Back to Square One?
title_sort probiotics in inflammatory bowel disease: are we back to square one?
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536108/
https://www.ncbi.nlm.nih.gov/pubmed/33042686
http://dx.doi.org/10.7759/cureus.10247
work_keys_str_mv AT puvvadasuvarnarekha probioticsininflammatoryboweldiseasearewebacktosquareone
AT luvsannyamenkhmaa probioticsininflammatoryboweldiseasearewebacktosquareone
AT pateldhara probioticsininflammatoryboweldiseasearewebacktosquareone
AT hassanzaira probioticsininflammatoryboweldiseasearewebacktosquareone
AT hamidpousette probioticsininflammatoryboweldiseasearewebacktosquareone